Evidence map›Paper›PMID 36044248›Full record

ArticleBriefings in bioinformatics2022

IgIDivA: immunoglobulin intraclonal diversification analysis.

Laura Zaragoza-Infante, Valentin Junet, Nikos Pechlivanis, Styliani-Christina Fragkouli, Serovpe Amprachamian, Triantafyllia Koletsa, Anastasia Chatzidimitriou, Maria Papaioannou, Kostas Stamatopoulos, Andreas Agathangelidis and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Briefings in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Laura Zaragoza-InfanteInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.ORCID 0000-0003-0207-257X
Valentin JunetAnaxomics Biotech SL, Barcelona, Spain.ORCID 0000-0002-6138-0612
Nikos PechlivanisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Styliani-Christina FragkouliInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.ORCID 0000-0003-4067-7123
Serovpe AmprachamianInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Triantafyllia KoletsaDepartment of Pathology, School of Medicine, Aristotle University of Thessaloniki.
Anastasia ChatzidimitriouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Maria PapaioannouHematology Unit, 1st Dept of Internal Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Andreas AgathangelidisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Fotis PsomopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.ORCID 0000-0002-0222-4273
Centre for Research and Technology Hellas · GRAristotle University of Thessaloniki · GRKarolinska Institutet · SENational and Kapodistrian University of Athens · GRUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraclonal diversification (ID) within the immunoglobulin (IG) genes expressed by B cell clones arises due to ongoing somatic hypermutation (SHM) in a context of continuous interactions with antigen(s). Defining the nature and order of appearance of SHMs in the IG genes can assist in improved understanding of the ID process, shedding light into the ontogeny and evolution of B cell clones in health and disease. Such endeavor is empowered thanks to the introduction of high-throughput sequencing in the study of IG gene repertoires. However, few existing tools allow the identification, quantification and characterization of SHMs related to ID, all of which have limitations in their analysis, highlighting the need for developing a purpose-built tool for the comprehensive analysis of the ID process. In this work, we present the immunoglobulin intraclonal diversification analysis (IgIDivA) tool, a novel methodology for the in-depth qualitative and quantitative analysis of the ID process from high-throughput sequencing data. IgIDivA identifies and characterizes SHMs that occur within the variable domain of the rearranged IG genes and studies in detail the connections between identified SHMs, establishing mutational pathways. Moreover, it combines established and new graph-based metrics for the objective determination of ID level, combined with statistical analysis for the comparison of ID level features for different groups of samples. Of importance, IgIDivA also provides detailed visualizations of ID through the generation of purpose-built graph networks. Beyond the method design, IgIDivA has been also implemented as an R Shiny web application. IgIDivA is freely available at https://bio.tools/igidiva.

Indexed as

Genes, ImmunoglobulinImmunoglobulinsB-LymphocytesClone CellsHigh-Throughput Nucleotide SequencingImmunoglobulinsB cell receptor immunoglobulingraph metricsgraph networkshigh-throughput sequencingintraclonal diversification

Identifiers

PMID36044248
PMCPMC9487589
OpenAlexW4293802793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.